- Home
- Applications
- namibia
- liquid biopsy
Liquid Biopsy Product Applications Available In Namibia
7 applications found
SNAQ-SEQ ctDNA spike-in standards Liquid biopsies offer the promise of earlier detection and monitoring of cancer patients’ treatment progression. However, as applications increasingly rely on ultra low variant allele frequency detection, NGS-based assays are beset with significantly more noise below 0.5% VAF that increases the rate of false positives. Laboratories looking to implement ctDNA assays need better quality controls that can ensure accurate detection and reporting by variant calling ...
ByAccuGenomics, Inc. based in Wilmington, NORTH CAROLINA (USA)
In 2022, nearly 30,000 Alabama men and women will be diagnosed with cancer, and more than 10,000 will die from the disease. The Information is Power campaign facilitated through the HudsonAlpha Institute for Biotechnology has offered free or reduced-cost hereditary cancer risk testing to our community of Northern Alabama in collaboration with Kailos Genetics since 2015. Information is Power uses the Expedio™ Hereditary Cancer Screening Service to review 33 genes for genetic mutations that may increase your ...
ByKailos Genetics, LLC. based in Huntsville, ALABAMA (USA)
You need a complete answer to provide the best ...
ByBiocept based in San Diego, CALIFORNIA (USA)
High Performance Across the Breadth of Biotech. The NX One is a perfect fit for a wide variety of sectors and application areas spanning fundamental biological research to industrial and clinical workflows. Access your cells faster and at a fraction of the ...
ByNodexus Inc. based in Hayward, CALIFORNIA (USA)
Non-small cell lung cancer (NSCLC) is not a single disease, but a collection of cancer types whose pathology is classified by histology (cells) and molecular profiling (genetic and protein ...
ByBiocept based in San Diego, CALIFORNIA (USA)
Standard treatment for advanced colorectal cancer generally involves surgical resection and chemotherapy. However, the recent emergence of targeted therapies, particularly those that inhibit EGFR, has provided treatment options that extend survival for a subset of patients. Unfortunately, this benefit does not extend to patients whose tumors contain mutations in EGFR signaling components KRAS and BRAF, which together represent 50% of all colorectal cancers. This makes characterizing these molecular markers an ...
ByBiocept based in San Diego, CALIFORNIA (USA)
A liquid biopsy from Biocept gives you a new tool for profiling breast cancer—with a simple blood ...
ByBiocept based in San Diego, CALIFORNIA (USA)